Newsroom | 39180 results

VENLO, Netherlands & HILDEN, Germany--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the commercial launch of QIAsymphony Connect, an IVD-compliant platform for automated clinical nucleic acid extraction. Building on the trusted QIAsymphony platform, with more than 3,300 cumulative placements worldwide, QIAsymphony Connect helps clinical laboratories standardize extraction across diverse assay workflows. The platform delivers highly concentrated DNA and...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell and in vivo CAR T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for ADI-212 for the treatment of patients with metastatic castration-resistant prostate cancer (m...

HUNTSVILLE, Ala.--(BUSINESS WIRE)--Today, Auburn University’s Applied Research Institute (AUARI) announced the installation of its new superconducting 200 MeV proton accelerator, an important step in opening the nation’s first university-led proton testing facility dedicated to qualifying space electronics. The RAD-FX-200 superconducting synchrocyclotron, manufactured and installed by Mevion Medical Systems, is the centerpiece of AUARI’s new Radiation Hardening Facility, created to address the...

WISCONSIN--(BUSINESS WIRE)--Susan G. Komen®, the world's leading breast cancer organization, today announced it will host the Wisconsin MORE THAN PINK Walk bringing together survivors, those living with metastatic breast cancer, families and supporters for a day of purpose and action. The event, taking place on Sunday, September 27, 2026, will raise critical funds to accelerate lifesaving research, expand patient support services, support critical public policy efforts and help ensure every per...

MEMPHIS, Tenn.--(BUSINESS WIRE)--This September, supporters across the country will rally behind St. Jude Children's Research Hospital®, joining a nationwide movement to raise awareness and funds for children with cancer and other life-threatening diseases. “While children and families face childhood cancer every day, Childhood Cancer Awareness Month is an important opportunity to shine a light on the challenges they endure and how they are counting on us to accelerate progress,” said Ike Anand...

WEST CHESTER, Ohio--(BUSINESS WIRE)--LetsGetChecked now offers the most comprehensive FDA-cleared at-home HPV screening tool available in the U.S....

MIAMI & LEAWOOD, Kan.--(BUSINESS WIRE)--The American Medical Society for Sports Medicine (AMSSM) and OpenEvidence today announced a partnership that will focus on co-developing AI-powered educational resources on sports medicine for both patients and clinicians. This exclusive collaboration brings the expertise of AMSSM’s sports medicine physicians to OpenEvidence, the leading AI-powered clinical decision support platform, and will build on the AMSSM’s robust foundation of educational materials....

TOLEDO, Ohio--(BUSINESS WIRE)--Susan G. Komen®, the world's leading breast cancer organization, today announced it will host the Northwest Ohio Race for the Cure bringing together survivors, those living with metastatic breast cancer, families and supporters for a day of purpose and action. The event, taking place on Sunday, September 27, 2026, will raise critical funds to accelerate lifesaving research, expand patient support services, support critical public policy efforts and help ensure ever...

TOKYO--(BUSINESS WIRE)--The first patient has been dosed in a first-in-human phase 1 trial evaluating DS1025 in adult patients with advanced or metastatic solid tumors with disease progression on or after at least one prior line of standard therapy. DS1025 is a specifically engineered, investigational, potential first-in-class CD25 directed antibody drug conjugate (ADC) containing an immuno-oncology optimized cytotoxic payload discovered by Daiichi Sankyo (TSE:4568). CD25 is a cell surface prot...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a new Signatera collaboration with Angiex, Inc., a privately held biotech company developing a portfolio of Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs). Angiex is conducting a Phase I clinical trial of AGX101, an investigational TM4SF1-directed ND-ADC. AGX101 is designed to bind TM4SF1 and deliver a cytotoxic payload to TM4SF1-expressing tumor cells and...